Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Guillermo Montalban-Bravo, Nicholas James Short, Naval Guastad Daver, Yesid Alvarado, Kelly Sharon Chien, Elias Jabbour, Gautam Borthakur, Mahesh Swaminathan, Abhishek Maiti, Danielle Hammond, Ghayas C. Issa, Lucia Masarova, Prithviraj Bose, Xuelin Huang, Heather Schneider, Kristy Bodden, Lizabeth Romero, Tapan M. Kadia, Hagop M. Kantarjian, Guillermo Garcia-Manero
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410809538